Reversal of docetaxel resistance with bevacizumab and thalidomide

Clinical Genitourinary Cancer

Volumn 7, Issue 2, 2009, Pages

  Ning, Yang Min ^a   Figg, William ^b   Dahut, William ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antiangiogenesis; Castration resistant prostate cancer; Reversal of taxane resistance

Indexed keywords

BEVACIZUMAB; DOCETAXEL; ENOXAPARIN; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; THALIDOMIDE;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CASE REPORT; CASTRATION; COMPUTER ASSISTED TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; LUNG EMBOLISM; MALE; METASTASIS; PROSTATE CANCER; TREATMENT RESPONSE;

EID: 70449345814     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2009.n.020     Document Type: Article

References (9)

1. Aragon-Ching JB, Dahut DL. Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression? Cancer Ther 2007; 5A:151-160
2. Ning YM, Gulley J, Arlen P, et al. Phase II trial of thalidomide, bevacizumab, and docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2008; 26(15 suppl):250s (Abstract 5000).
3. Bubley G, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in adrogen independent prostate cancer: recommendations from the PSA Working Group. J Clin Oncol 1999; 17:3461-3467
4. Eymard J, Oudard S, Gravis G, et al. Second-line chemotherapy with docetaxel (D) in men treated with docetaxel-based regimen for metastatic hormone-refractory prostate cancer (mHRPC). Presented at: the 2007 Prostate Cancer Symposium; Abstract 249.
5. Di Lorenzo G, Figg W, Fossa S, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008; 54:1089-1096
6. Ross RW, Beer TM, Jacobus S, et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 2008; 112:521-526
7. Dickson PV, Hamner JB, Sims TL, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007; 13:3942-3950
8. Ansiaux R, Baudelet C, Jordan BF, et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005; 11:743-750
9. Kyle AH, Huxham LA, Yeoman DM, et al. Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin Cancer Res 2007; 13:2804-2810